<\/p>\n
Roliten<\/strong> obsahuje tolterodin tartr\u00e1t<\/strong> — a competitive muscarinic acetylcholine receptor antagonist used to treat hyperaktivn\u00edho mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e (OAB)<\/strong> with urgency, frequency, and urge incontinence. Available as 1 mg immediate-release tablets. Standard dose: 2 mg twice daily<\/strong> (or 1 mg twice daily in renal\/hepatic impairment or with strong CYP3A4 inhibitors). For convenient once-daily dosing with smoother side-effect profile, see the extended-release formulation (Terol LA)<\/a>. Tolterodine is generally better tolerated than oxybutynin<\/strong> — less dry mouth, less constipation, and lower CNS penetration. Use with caution in adults aged 65+<\/strong> — the 2023 American Geriatrics Society Beers Criteria classifies all anticholinergic OAB drugs as “potentially inappropriate” in older adults due to cumulative anticholinergic burden. Mirabegron (Mirago)<\/strong> is the preferred first-line OAB drug in this population.<\/p>\n<\/div>\n \ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n <\/p>\n Ka\u017ed\u00e1 \u0161ar\u017ee je dod\u00e1v\u00e1na od v\u00fdrobce certifikovan\u00e9ho WHO-GMP<\/strong>. Objedn\u00e1vky jsou expedov\u00e1ny v nen\u00e1padn\u00fdch obalech bez loga od na\u0161ich partnersk\u00fdch sklad\u016f a jsou pokryty na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a>: pokud z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, za\u0161leme zdarma n\u00e1hradn\u00ed z\u00e1silku, bez dotaz\u016f.<\/p>\n Roliten is a brand of tolterodine tartrate 1 mg immediate-release tablets<\/strong>. Tolterodine is one of the most-prescribed antimuscarinic OAB drugs worldwide. Internationally branded as Detrol \/ Detrol LA (US), Detrusitol \/ Detrusitol XL (UK \/ EU)<\/strong>. Pack sizes available at MedsBase: 30, 60, 90 or 180 tablets\/capsules.<\/p>\n Tolterodine is a competitive antagonist at M2 and M3 muscarinic acetylcholine receptors<\/strong>. Bladder M3 blockade reduces parasympathetic-driven detrusor contractions during the filling phase — decreasing urgency and incontinence episodes and increasing functional bladder capacity.<\/p>\n Ve srovn\u00e1n\u00ed s oxybutynin<\/a>, tolterodine has somewhat better selectivity for bladder vs salivary-gland muscarinic receptors, lower CNS penetration, and a more favourable side-effect profile — particularly less severe dry mouth. Both are still anticholinergics with the standard class warnings about elderly use.<\/p>\n Tolterodine is metabolised by CYP2D6 to an active metabolite (5-hydroxymethyl tolterodine) which contributes substantially to clinical effect. About 5-10% of the population are CYP2D6 “poor metabolisers” who form less of the metabolite and need dose adjustment.<\/p>\n Tolterodine has somewhat lower CNS penetration than oxybutynin and is generally considered the better-tolerated of the two anticholinergic OAB drugs in older adults — but it is still classified as “potentially inappropriate” in the Beers Criteria and should be used cautiously and at the lowest effective dose. Mirabegron remains the preferred first-line OAB drug in adults aged 65+<\/strong> when affordable and not contraindicated by hypertension.<\/p>\n Do not take tolterodine if you have:<\/strong><\/p>\n Pou\u017e\u00edvejte s opatrnost\u00ed, pokud m\u00e1te:<\/strong> elderly age (see above), benign prostatic hyperplasia (urinary retention risk), reflux oesophagitis, autonomic neuropathy, congenital or acquired QT prolongation, coronary artery disease.<\/p>\nPro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
\n
What is Roliten?<\/h2>\n
How tolterodine works<\/h2>\n
When tolterodine is used<\/h2>\n
\n
D\u00e1vkov\u00e1n\u00ed & zp\u016fsob u\u017e\u00edv\u00e1n\u00ed<\/h2>\n
\n
Vedlej\u0161\u00ed \u00fa\u010dinky & bezpe\u010dnost<\/h2>\n
\n
Anticholinergic burden & the elderly<\/h2>\n
Kontraindikace a varov\u00e1n\u00ed<\/h2>\n
\n
Interakce l\u00e9k\u016f<\/h2>\n
\n
How tolterodine compares<\/h2>\n